{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T22:32:26Z","timestamp":1649025146182},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,27]],"date-time":"2014-11-27T00:00:00Z","timestamp":1417046400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s12032-014-0402-0","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T14:21:49Z","timestamp":1417443709000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Topotecan combined with Ifosfamide, Etoposide, and l-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma"],"prefix":"10.1007","volume":"32","author":[{"given":"YaJuan","family":"Shao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ShuChang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YuZhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,27]]},"reference":[{"issue":"11","key":"402_CR1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"The Non-Hodgkin\u2019s Lymphoma Classification Project","year":"1997","unstructured":"The Non-Hodgkin\u2019s Lymphoma Classification Project. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin\u2019s lymphoma. Blood. 1997;89(11):3909\u201318.","journal-title":"Blood"},{"issue":"3","key":"402_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","volume":"138","author":"J Sun","year":"2012","unstructured":"Sun J, Yang Q, Lu Z, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138(3):429\u201334.","journal-title":"Am J Clin Pathol"},{"issue":"15","key":"402_CR3","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","volume":"120","author":"YL Kwong","year":"2012","unstructured":"Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012;120(15):2973\u201380.","journal-title":"Blood"},{"issue":"4","key":"402_CR4","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1007\/s12032-013-0720-7","volume":"30","author":"L Yang","year":"2013","unstructured":"Yang L, Liu H, Xu XH, et al. Retrospective study of modified SMILE chemotherapy for advanced-stage, relapsed, or refractory extranodal natural killer (NK)\/T cell lymphoma, nasal type. Med Oncol. 2013;30(4):720\u20136.","journal-title":"Med Oncol"},{"issue":"46","key":"402_CR5","first-page":"3257","volume":"92","author":"LY Ping","year":"2012","unstructured":"Ping LY, Zheng W, Wang XP. Safety and adverse event profiling of pegylated L-asparaginase combined chemotherapy in the treatment of lymphoma. Zhong Hua Yi Xue Za Zhi. 2012;92(46):3257\u201360.","journal-title":"Zhong Hua Yi Xue Za Zhi"},{"issue":"8","key":"402_CR6","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1007\/s12010-012-9755-z","volume":"167","author":"LN Ramya","year":"2012","unstructured":"Ramya LN, Doble M, Rekha VP. L-asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia. Appl Biochem Biotechnol. 2012;167(8):2144\u201359.","journal-title":"Appl Biochem Biotechnol"},{"issue":"2","key":"402_CR7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF02983387","volume":"78","author":"W Yong","year":"2003","unstructured":"Yong W, Zheng W, Zhang Y, et al. L-asparaginase-based regimen in the treatment of refractory midline nasal\/nasal-type T\/NK-cell lymphoma. Int J Hematol. 2003;78(2):163\u20137.","journal-title":"Int J Hematol"},{"issue":"2","key":"402_CR8","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1081\/CNV-120001143","volume":"20","author":"EH Kraut","year":"2002","unstructured":"Kraut EH, Balcerzak SP, Young D, et al. A phase II study of topotecan in non-Hodgkin\u2019s lymphoma: an Ohio State University phase II research consortium study. Cancer Invest. 2002;20(2):174\u20139.","journal-title":"Cancer Invest"},{"issue":"6","key":"402_CR9","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.3109\/10428194.2011.643406","volume":"53","author":"PH Wiernik","year":"2012","unstructured":"Wiernik PH, Li H, Weller E, et al. Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493). Leuk Lymphoma. 2012;53(6):1137\u201342.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"402_CR10","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1080\/1042819021000002901","volume":"43","author":"M Crump","year":"2002","unstructured":"Crump M, Couban S, Meyer R, et al. Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin\u2019s lymphoma: a National Cancer Institute of Canada Clinical Trials Group study. Leuk Lymphoma. 2002;43(8):1581\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"402_CR11","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418\u201325.","journal-title":"Blood"},{"issue":"25","key":"402_CR12","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124\u201330.","journal-title":"J Clin Oncol"},{"issue":"10","key":"402_CR13","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"MP Escalon","year":"2005","unstructured":"Escalon MP, Liu NS, Yang Y, et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M.D. Anderson Cancer Center experience. Cancer. 2005;103(10):2091\u20138.","journal-title":"Cancer"},{"issue":"2","key":"402_CR14","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3892\/or.2012.2143","volume":"29","author":"N Iriyama","year":"2012","unstructured":"Iriyama N, Takahashi H, Hatta Y, et al. Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral T-cell lymphomas. Oncol Rep. 2012;29(2):805\u201311.","journal-title":"Oncol Rep"},{"key":"402_CR15","first-page":"269","volume":"6","author":"MF Cheng","year":"1994","unstructured":"Cheng MF, Chatterjee S, Berger NA. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res. 1994;6:269\u201379.","journal-title":"Oncol Res"},{"issue":"11","key":"402_CR16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/jnci\/88.11.734","volume":"88","author":"SH Kaufmann","year":"1996","unstructured":"Kaufmann SH, Peereboom D, Buckwalter CA, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst. 1996;88(11):734\u201341.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"402_CR17","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1080\/10428190600581385","volume":"47","author":"SM Smith","year":"2006","unstructured":"Smith SM, Johnson JL, Niedzwiecki D, et al. Sequential doxorubicin and topotecan in relapsed\/refractory aggressive non-Hodgkin\u2019s lymphoma: results of CALGB 59906. Leuk Lymphoma. 2006;47(8):1511\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"402_CR18","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1158\/1078-0432.CCR-11-1540","volume":"17","author":"JB Perkins","year":"2011","unstructured":"Perkins JB, Goldstein SC, Dawson JL, et al. Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamics correlates. Clin Cancer Res. 2011;17(24):7743\u201353.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"402_CR19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-007-9464-6","volume":"86","author":"AD Voloschin","year":"2008","unstructured":"Voloschin AD, Betensky R, Wen PY, et al. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neuro Oncol. 2008;86(2):211\u20135.","journal-title":"J Neuro Oncol"},{"issue":"1","key":"402_CR20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/07388550601173926","volume":"27","author":"N Verma","year":"2007","unstructured":"Verma N, Kumar K, Kaur G, et al. L-asparaginase: a promising chemotherapeutic agent. Crit Rev Biotechnol. 2007;27(1):45\u201362.","journal-title":"Crit Rev Biotechnol"},{"issue":"7","key":"402_CR21","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3109\/10428194.2012.742521","volume":"54","author":"FM Foss","year":"2013","unstructured":"Foss FM, Sjak-Shie N, Goy A, et al. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study. Leuk Lymphoma. 2013;54(7):1373\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"402_CR22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","volume":"31","author":"G Damaj","year":"2013","unstructured":"Damaj G, Gressin R, Bouabdallah K, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013;31(1):104\u201310.","journal-title":"J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0402-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-014-0402-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-014-0402-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T10:57:19Z","timestamp":1598525839000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-014-0402-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,27]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["402"],"URL":"https:\/\/doi.org\/10.1007\/s12032-014-0402-0","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,27]]},"article-number":"402"}}